Sentiment Report: Insulet Corp (NASDAQ:PODD)

Insulet Corporation (NASDAQ:PODD) Logo

Sentiment for Insulet Corp (NASDAQ:PODD)

Insulet Corp (NASDAQ:PODD) institutional sentiment decreased to 0.95 in Q3 2018. Its down -0.46, from 1.41 in 2018Q2. The ratio turned negative, as 102 institutional investors opened new and increased positions, while 107 decreased and sold their equity positions in Insulet Corp. The institutional investors in our partner’s database now hold: 62.28 million shares, up from 60.77 million shares in 2018Q2. Also, the number of institutional investors holding Insulet Corp in their top 10 positions decreased from 5 to 3 for a decrease of 2. Sold All: 31 Reduced: 76 Increased: 58 New Position: 44.

Insulet Corporation, a medical device company, develops, makes, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company has market cap of $4.32 billion. The firm offers Omnipod Insulin Management System , which consists of the OmniPod, an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It currently has negative earnings. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas.

The stock decreased 1.58% or $1.17 during the last trading session, reaching $73.05. About 600,153 shares traded. Insulet Corporation (NASDAQ:PODD) has risen 20.02% since January 12, 2018 and is uptrending. It has outperformed by 20.02% the S&P500.

Analysts await Insulet Corporation (NASDAQ:PODD) to report earnings on February, 20. They expect $0.06 earnings per share, up 150.00 % or $0.18 from last year’s $-0.12 per share. PODD’s profit will be $3.54M for 304.38 P/E if the $0.06 EPS becomes a reality. After $0.03 actual earnings per share reported by Insulet Corporation for the previous quarter, Wall Street now forecasts 100.00 % EPS growth.

Shaker Investments Llc Oh holds 4.56% of its portfolio in Insulet Corporation for 69,625 shares. Tirschwell & Loewy Inc owns 297,580 shares or 3.94% of their US portfolio. Moreover, Kopp Investment Advisors Llc has 3.31% invested in the company for 37,072 shares. The California-based Rosenblum Silverman Sutton S F Inc Ca has invested 1.97% in the stock. Frontier Capital Management Co Llc, a Massachusetts-based fund reported 1.95 million shares.

Since January 1, 0001, it had 0 insider purchases, and 8 sales for $1.34 million activity.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Ratings analysis reveals 50% of Insulet’s analysts are positive. Out of 2 Wall Street analysts rating Insulet, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $90 while the high is $105. The stock’s average target of $97.50 is 33.47% above today’s ($73.05) share price. PODD was included in 3 notes of analysts from October 11, 2018. As per Thursday, October 11, the company rating was maintained by Morgan Stanley. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, January 2.

More notable recent Insulet Corporation (NASDAQ:PODD) news were published by: which released: “Omnipod insulin management system now available for use in Europe with Fiasp – Seeking Alpha” on October 02, 2018, also with their article: “Insulet (PODD) Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” published on November 01, 2018, published: “Here’s Why Tandem Diabetes Care Is Jumping 16% Today – The Motley Fool” on November 21, 2018. More interesting news about Insulet Corporation (NASDAQ:PODD) were released by: and their article: “Insulet to Present at the 37th Annual J.P. Morgan Healthcare Conference – Business Wire” published on December 18, 2018 as well as‘s news article titled: “New chief at Insulet – Seeking Alpha” with publication date: September 10, 2018.

Insulet Corporation (NASDAQ:PODD) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.